AR100729A1 - PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE - Google Patents

PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE

Info

Publication number
AR100729A1
AR100729A1 ARP150101769A ARP150101769A AR100729A1 AR 100729 A1 AR100729 A1 AR 100729A1 AR P150101769 A ARP150101769 A AR P150101769A AR P150101769 A ARP150101769 A AR P150101769A AR 100729 A1 AR100729 A1 AR 100729A1
Authority
AR
Argentina
Prior art keywords
frequency
pharmaceutical composition
reduce
miction
pharmaceutical formulation
Prior art date
Application number
ARP150101769A
Other languages
Spanish (es)
Inventor
J Rauscher Frank Iii
A Dill David
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/298,511 external-priority patent/US9532959B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of AR100729A1 publication Critical patent/AR100729A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos y composiciones para reducir la frecuencia de micción. Los métodos comprenden administrar a un sujeto que tiene una condición que genera una frecuencia no deseada de micción una cantidad eficaz de una composición farmacéutica que comprende uno o más inhibidores de la vía de prostaglandinas. Las composiciones farmacéuticas comprenden uno o más inhibidores de la vía de las prostaglandinas y un transportador farmacéuticamente aceptable. Reivindicación 24: La composición farmacéutica de la reivindicación 17, caracterizada porque además comprende un analgésico. Reivindicación 25: La composición farmacéutica de la reivindicación 24, caracterizada porque dicho analgésico es acetaminofeno. Reivindicación 26: La composición farmacéutica de la reivindicación 24, caracterizada porque además comprende un agente antimuscarínico, un antidiurético, un espasmolitico o zolpidem.Methods and compositions to reduce the frequency of urination. The methods comprise administering to an individual having a condition that generates an unwanted frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Claim 24: The pharmaceutical composition of claim 17, characterized in that it further comprises an analgesic. Claim 25: The pharmaceutical composition of claim 24, characterized in that said analgesic is acetaminophen. Claim 26: The pharmaceutical composition of claim 24, characterized in that it further comprises an antimuscarinic agent, an antidiuretic, a spasmolytic or zolpidem.

ARP150101769A 2014-06-06 2015-06-04 PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE AR100729A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/298,511 US9532959B2 (en) 2010-07-08 2014-06-06 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
AR100729A1 true AR100729A1 (en) 2016-10-26

Family

ID=58699848

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101769A AR100729A1 (en) 2014-06-06 2015-06-04 PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE

Country Status (1)

Country Link
AR (1) AR100729A1 (en)

Similar Documents

Publication Publication Date Title
CO2020000145A2 (en) Carboxamides as sodium channel modulators
DOP2019000005A (en) 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
CL2017000240A1 (en) Active compounds towards bromodominiums
NI201600051A (en) COMBINATIONS OF HISTONE DESACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS
CL2013000063A1 (en) A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.
CR20160433A (en) NEW COMPOUNDS
RS54584B1 (en) Compositions comprising 15-hepe and methods of using the same
MX2022001796A (en) Methods and compositions to inhibit symptoms associated with veisalgia.
MX2019008817A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof.
CL2015002181A1 (en) Treatment of progressive forms of multiple sclerosis with laquinimod.
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
UY34896A (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE
AR100784A1 (en) MULTICOMPONENT MICROPARTURES FOR USE IN AN INHALABLE FORMULATION, PROCESS TO PREPARE, PHARMACEUTICAL FORMULATION, INHALER
BR112015001627A2 (en) pharmaceutical composition, their uses and method of decreasing the frequency of urination
CR20160432A (en) WNT SIGNALING ROAD INHIBITORS
MX2016016039A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof.
CL2016001843A1 (en) Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal.
BR112013004714A2 (en) "combinations of hdac inhibitors with thrombocytopenia drugs and their uses"
CL2018002200A1 (en) Combined administration of a penetrating agent and a sulfur compound containing compound for plants.
UY35445A (en) LIPOEQUILIBRATED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL ADMINISTRATION
AR100729A1 (en) PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE
CL2016002655A1 (en) Pharmaceutical composition for the treatment of pain-related allopathies, using as active agent ketorolac tromethamine and tramadol hydrochloride
MX2017003878A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof.
TW201611830A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure